Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis
- 21 June 2001
- journal article
- Published by Springer Nature in Oncogene
- Vol. 20 (28) , 3620-3628
- https://doi.org/10.1038/sj.onc.1204495
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 73 references indexed in Scilit:
- Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cellsOncogene, 2000
- Expression of Integrated Hepatitis B Virus X Variants in Human Hepatocellular Carcinomas and Its SignificanceBiochemical and Biophysical Research Communications, 2000
- Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasomeOncogene, 1998
- Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell DeathCell, 1996
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Geographic Variation of p53 Mutational Profile in Nonmalignant Human LiverScience, 1994
- Doing the right thing: feedback control and p53Current Opinion in Cell Biology, 1993
- p53, guardian of the genomeNature, 1992
- In vitro tumorigenicity of hepatitis B virus DNA and HBx proteinJournal of Hepatology, 1991